ArticleCureus2023
Psoriasis and Its Relationship With Somatosensory Amplification, Health Anxiety, and Depression.
Article in Cureus, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed, 4 citations in OpenAlex.
- Relative Efficacy of Immunomodulatory Monotherapies for Psoriasis of the Scalp: A Network Meta-Analysis Study.Journal of cosmetic dermatology · 2026Article
- Tanshinone I Ameliorates Psoriasis-Like Dermatitis by Suppressing Inflammation and Regulating Keratinocyte Differentiation.Drug design, development and therapy · 2025Article
- The Depressiveness, Quality of Life and NEO-FFI Scale in Patients with Selected Genodermatoses.Journal of clinical medicine · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective The present study investigates the relationship between psoriasis and diseases such as health anxiety, depression, and somatosensory amplification. Methods The participating patients (n=117, including 60 psoriasis patients and 57 controls) filled out the Beck Depression Inventory (BDI), Beck Anxiety Inventory (BAI), Somatosensory Amplification Scale (SSAS), and Health Anxiety Inventory (HAI) questionnaires. Results The mean scores from SSAS, HAI, and BDI were significantly higher in the psoriasis group than in the control group (p<0.05 in all comparisons). When the group medians of BAI were evaluated, the differences were not statistically significant, although BAI medians were higher in the patient group. Furthermore, a moderate correlation was found between the involvement of specific areas (especially the scalp and face) and SSAS scores. Conclusion Patients with psoriasis score highly in depression, health anxiety, and somatosensory amplification, and there was a moderate correlation between specific body area involvement (especially the scalp and face) and SSAS score. The results of this study seem to indicate that psychiatric assessment and treatment approaches should be included in the treatment of such chronic skin diseases as psoriasis that follow a life-long remission and relapse pattern.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.